VERU

Veru Inc

VERU, USA

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

https://verupharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VERU
stock
VERU

VERU Earnings Preview: Recent $VERU Insider Trading, Hedge Fund Activity, and More Quiver Quantitative

Read more →
VERU
stock
VERU

Treasury Yields: Why VERU stock attracts high net worth investors - Day Trade & Free Growth Oriented Trading Recommendations moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

BUY

Target Price:

$19.75

Analyst Picks

Strong Buy

2

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

0.40

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

High

2.31

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-47.79 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-26.83 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Low

0.78

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 31.58% of the total shares of Veru Inc

1.

BlackRock Inc

(5.9033%)

since

2025/03/31

2.

MPM Oncology Impact Management LP

(4.5%)

since

2025/03/31

3.

Vanguard Group Inc

(4.3732%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(2.5982%)

since

2025/07/31

5.

State Street Corp

(1.5249%)

since

2025/03/31

6.

UBS Group AG

(1.3425%)

since

2025/03/31

7.

Geode Capital Management, LLC

(1.0964%)

since

2025/06/30

8.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0835%)

since

2025/07/31

9.

Ikarian Capital, LLC

(0.9728%)

since

2025/03/31

10.

Oppenheimer & Co Inc

(0.8962%)

since

2025/06/30

11.

Deutsche Bank AG

(0.7521%)

since

2025/03/31

12.

Northern Trust Corp

(0.7152%)

since

2025/03/31

13.

Xtrackers MSCI World Swap ETF 1C

(0.7077%)

since

2025/07/31

14.

Adage Capital Partners Gp LLC

(0.6826%)

since

2025/03/31

15.

Fidelity Extended Market Index

(0.4822%)

since

2025/07/31

16.

Envestnet Asset Management Inc

(0.423%)

since

2025/06/30

17.

Susquehanna International Group, LLP

(0.3557%)

since

2025/03/31

18.

180 WEALTH ADVISORS, LLC

(0.3132%)

since

2025/06/30

19.

BOOTHBAY FUND MANAGEMENT, LLC

(0.2766%)

since

2025/03/31

20.

Blair William & Co

(0.2594%)

since

2025/06/30

21.

Morgan Stanley - Brokerage Accounts

(0.2569%)

since

2025/03/31

22.

Charles Schwab Investment Management Inc

(0.2562%)

since

2025/03/31

23.

Cubist Systematic Strategies, LLC

(0.2467%)

since

2025/06/30

24.

Goldman Sachs Group Inc

(0.1973%)

since

2025/03/31

25.

Fidelity Total Market Index

(0.1584%)

since

2025/07/31

26.

Extended Equity Market Fund K

(0.1483%)

since

2025/06/30

27.

T. Rowe Price U.S. Equities Tr

(0.1298%)

since

2025/06/30

28.

Fidelity Series Total Market Index

(0.1293%)

since

2025/07/31

29.

Spartan Extended Market Index Pool F

(0.1013%)

since

2025/07/31

30.

NT Ext Equity Mkt Idx Fd - L

(0.0921%)

since

2025/06/30

31.

Northern Trust Extended Eq Market Idx

(0.0921%)

since

2025/06/30

32.

NT Ext Equity Mkt Idx Fd - NL

(0.0771%)

since

2025/06/30

33.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0598%)

since

2025/06/30

34.

Spartan Total Market Index Pool G

(0.0594%)

since

2025/07/31

35.

Fidelity Nasdaq Composite Index

(0.0582%)

since

2025/07/31

36.

Goldman Sachs Absolute Ret Trckr Instl

(0.0577%)

since

2025/06/30

37.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.0558%)

since

2025/07/31

38.

Fidelity ZERO Total Market Index

(0.0509%)

since

2025/07/31

39.

Vanguard Balanced Index Inv

(0.0454%)

since

2025/07/31

40.

Schwab Total Stock Market Index

(0.0444%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

-0.0567

EPS Difference

0.0567

Surprise Percent

100%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.